Clarithromycin plus intravenous immunoglobulin therapy can reduce the relapse rate of Kawasaki disease: A phase 2, open-label, randomized control study

Etsuro Nanishi, Hisanori Nishio, Hidetoshi Takada, Kenichiro Yamamura, Mitsuharu Fukazawa, Kenji Furuno, Yumi Mizuno, Kenjiro Saigo, Ryo Kadoya, Noriko Ohbuchi, Yasuhiro Onoe, Hironori Yamashita, Hideki Nakayama, Takuya Hara, Takuro Ohno, Yasuhiko Takahashi, Ken Hatae, Tatsuo Harada, Takayuki Shimose, Junji KishimotoShouichi Ohga, Toshiro Hara

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Clarithromycin plus intravenous immunoglobulin therapy can reduce the relapse rate of Kawasaki disease: A phase 2, open-label, randomized control study'. Together they form a unique fingerprint.

Medicine & Life Sciences